<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PYLERAÂ - bismuth subcitrate potassium, metronidazole and tetracycline hydrochlorideÂ capsuleÂ </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use PYLERA safely and effectively.  See full prescribing information for PYLERA. Initial U.S. Approval: 2006 
</div>
<div><div>To reduce the development of drug-resistant bacteria and maintain the effectiveness of PYLERA and other antibacterial drugs, PYLERA should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria. <a href="#section_1">(1)</a>
</div></div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">PYLERA is a combination antibacterial indicated for the treatment of patients with <span class="Italics">Helicobacter pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> disease (active or history of within the past 5 years) to eradicate <span class="Italics">H. pylori</span>. <a href="#section_1">(1.1)</a> </p>
<br>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li><p class="Highlighta">Each dose of PYLERA includes 3 capsules. <a href="#section_2">(2)</a> </p></li>
<li><p class="Highlighta">Each dose of PYLERA should be taken 4 times a day, after meals and at bedtime for 10 days. <a href="#section_2">(2)</a> </p></li>
<li><p class="Highlighta">Administer PYLERA with omeprazole 20 mg twice daily (after the morning and evening meals). <a href="#section_2">(2)</a> </p></li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">Each capsule of PYLERA contains: (<a href="#section_3">3</a>) </p>
<ul>
<li>140 mg of bismuth subcitrate potassium </li>
<li>125 mg of metronidazole  </li>
<li>125 mg of tetracycline hydrochloride</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. <a href="#section_%204">(4.4)</a>
</li>
<li>Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to product components. <a href="#section_4">(4.5)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Fetal Toxicity: Advise pregnant women of the risk for permanent discoloration of teeth with tetracycline if used during the second or third trimester <a href="#section-7"> (5.1,</a><a href="#section-10"> 8.1)</a>
</li>
<li>Maternal Toxicity: Risk of hepatotoxicity in pregnant women with high doses of intravenous tetracycline also resulting in stillborn or <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">premature birth</span> <a href="#section-7"> (5.2,</a><a href="#section-10"> 8.1)</a>
</li>
<li>Central and Peripheral Nervous System Effects: <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> with metronidazole, <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span> with tetracycline and <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> with bismuth-containing products; Monitor patients with CNS conditions closely and discontinue promptly if abnormal neurologic signs develop. <a href="#section-7">(5.4)</a>
</li>
<li>Development of <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">Superinfection</span>:  If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, discontinue PYLERA and institute appropriate therapy. <a href="#section-7"> (5.5)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span>: avoid exposure to sun and sun lamps. <a href="#section-7"> (5.6)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most frequently reported adverse reactions (â‰¥5%); <span class="product-label-link" type="condition" conceptid="437671" conceptname="Abnormal feces">abnormal feces</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. <a href="#section-8"> (6.1)</a> </p>
<p class="Highlighta"><span class="Bold"><br></span> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact AXCAN Pharma US, Inc. at 1-800-472-2634 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span>. </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Methoxyflurane: Risk of fatal renal toxicity; do not co-administer.Â  <a href="#section_4_1">(4.1</a>, <a href="#section_7_1">7.1)</a>
</li>
<li>Disulfiram: <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic reactions</span> can occur; do not take concurrently or within the last 2 weeks of disulfiram.Â  <a href="#section_4_2">(4.2</a>, <a href="#section_7_2">7.2)</a>
</li>
<li>Alcohol: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> can occur; do no consume during therapy and for at least 3 days afterwards.Â  <a href="#section_7_3">(7.3)</a>
</li>
<li>Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception.Â <a href="#section-9"> (7.4)</a><a href="#section-9"></a>
</li>
<li>Anticoagulants: Potentiation of the anticoagulant effect; <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time, International Normalized Ratio (INR), or other suitable anticoagulation tests should be closely monitored. <a href="#section_7_5">(7.5)</a>
</li>
<li>Lithium: Increased lithium serum concentrations; measure serum lithium and serum creatinine concentrations during therapy. <a href="#section_7_6">(7.6)</a>
</li>
<li>Antacids, Multivitamins or Dairy Products: Decreased absorption of PYLERA; do not take concomitantly.Â  <a href="#section_7_7">(7.7)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Nursing Mothers: Discontinue drug or nursing taking into consideration the importance of the drug to the mother. <a href="#section-10"> (8.3)</a>
</li>
<li>Pediatric Use: Tetracycline may cause permanent discoloration of the teeth.Â  <span class="product-label-link" type="condition" conceptid="4131814" conceptname="Enamel hypoplasia">Enamel hypoplasia</span> has also been reported.Â  Do not use in children less than 8 years of age. <a href="#section_5_3">(5.3,</a><a href="#section_8_4">8.4)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 3/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-2" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-2.1" class="toc">1.1	Eradication of <span class="Italics">Helicobacter pylori</span> in Patients with Active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> or History of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Disease</a></h2>
<h1><a href="#section-3" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-4" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-5" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-5.1" class="toc">4.1  Methoxyflurane</a></h2>
<h2><a href="#section-5.2" class="toc">4.2 Disulfiram</a></h2>
<h2><a href="#section-5.3" class="toc">4.3 Alcohol</a></h2>
<h2><a href="#section-5.4" class="toc">4.4 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-5.5" class="toc">4.5 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h1><a href="#section-6" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">5.1 Fetal Toxicity</a></h2>
<h2><a href="#section-6.2" class="toc">5.2	Maternal Toxicity</a></h2>
<h2><a href="#section-6.3" class="toc">5.3	Tooth Enamel Discoloration and Hypoplasia</a></h2>
<h2><a href="#section-6.4" class="toc">5.4	Central and Peripheral Nervous System Effects</a></h2>
<h2><a href="#section-6.5" class="toc">5.5	Development of <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">Superinfections</span></a></h2>
<h2><a href="#section-6.6" class="toc">5.6	<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span></a></h2>
<h2><a href="#section-6.7" class="toc">5.7	Darkening of the Tongue and/or Black Stool</a></h2>
<h2><a href="#section-6.8" class="toc">5.8	Use in Patients with <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood Dyscrasias</span></a></h2>
<h2><a href="#section-6.9" class="toc">5.9	Laboratory Test Interactions</a></h2>
<h2><a href="#section-6.10" class="toc">5.10	Development of Drug Resistant Bacteria</a></h2>
<h1><a href="#section-7" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h2><a href="#section-7.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h2><a href="#section-7.3" class="toc">6.3	Other Important Adverse Reactions from Labeling for the Individual Components of PYLERA</a></h2>
<h1><a href="#section-8" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-8.1" class="toc">7.1	Methoxyflurane</a></h2>
<h2><a href="#section-8.2" class="toc">7.2	Disulfiram</a></h2>
<h2><a href="#section-8.3" class="toc">7.3	Alcohol</a></h2>
<h2><a href="#section-8.4" class="toc">7.4	Oral Contraceptives</a></h2>
<h2><a href="#section-8.5" class="toc">7.5	Anticoagulants</a></h2>
<h2><a href="#section-8.6" class="toc">7.6	Lithium</a></h2>
<h2><a href="#section-8.7" class="toc">7.7	Antacids, Multivitamins, or Dairy Products</a></h2>
<h2><a href="#section-8.8" class="toc">7.8	Penicillin</a></h2>
<h2><a href="#section-8.9" class="toc">7.9	Inhibitors of CYP450 liver enzymes</a></h2>
<h2><a href="#section-8.10" class="toc">7.10	Inducers of CYP450 liver enzymes</a></h2>
<h1><a href="#section-9" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-9.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-9.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-9.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-9.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-9.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-9.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-12.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1 Eradication of <span class="Italics">Helicobacter pylori</span> in Patients with Active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> or History of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Disease 
</a></h2>
<h1><a href="#section-15" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-16" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-17" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-17.1" class="toc">17.1 Pregnant Women</a></h2>
<h2><a href="#section-17.2" class="toc">17.2 Human Milk Feeding</a></h2>
<h2><a href="#section-17.3" class="toc">17.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-17.4" class="toc">17.4 Central Nervous System Effects</a></h2>
<h2><a href="#section-17.5" class="toc">17.5 <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span></a></h2>
<h2><a href="#section-17.6" class="toc">17.6 Drug Interactions</a></h2>
<h2><a href="#section-17.7" class="toc">17.7 Darkening of the Tongue and/or Stool</a></h2>
<h2><a href="#section-17.8" class="toc">17.8 Dosing Information</a></h2>
<h2><a href="#section-17.9" class="toc">17.9 Administration with Fluids</a></h2>
<h2><a href="#section-17.10" class="toc">17.10 Antibacterial Resistance</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="section_0"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section_1"></a><a name="section-2"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of PYLERA and other antibacterial drugs, PYLERA should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria.  When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<br><div class="Section" data-sectionCode="42229-5">
<a name="section_1_1"></a><a name="section-2.1"></a><p></p>
<h2>1.1	Eradication of <span class="Italics">Helicobacter pylori</span> in Patients with Active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> or History of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Disease</h2>
<p class="First"> PYLERA in combination with omeprazole are indicated for the treatment of patients with <span class="Italics">Helicobacter pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> disease (active or history of within the past 5 years) to eradicate <span class="Italics">H. pylori</span>.  The eradication of <span class="Italics">Helicobacter pylori</span> has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> recurrence.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section_2"></a><a name="section-3"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Each dose of PYLERA is 3 capsules. Each dose of all 3 capsules should be taken 4 times a day, after meals and at bedtime for 10 days.  One omeprazole 20 mg capsule should be taken twice a day with PYLERA after the morning and evening meal for 10 days (<span class="Bold">Table 1</span>). </p>
<br><a name="table1"></a><table frame="box" width="100%">
<caption><span>Table 1: Daily Dosing Schedule for PYLERA</span></caption>
<colgroup>
<col align="left">
<col align="center">
<col align="center">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td align="left"><span class="Bold">Time of dose</span></td>
<td align="center"><span class="Bold">Number of capsules of PYLERA</span></td>
<td align="center"><span class="Bold">Number of capsules of Omeprazole 20 mg</span></td>
</tr>
<tr>
<td align="left">After morning meal</td>
<td align="center">3</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">After lunch</td>
<td align="center">3</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">After evening meal</td>
<td align="center">3</td>
<td align="center">1</td>
</tr>
<tr class="Last">
<td align="left">At bedtime</td>
<td align="center">3</td>
<td align="center">0</td>
</tr>
</tbody>
</table>
<br><p>Instruct patients to swallow the PYLERA capsules whole with a full glass of water (8 ounces).  Ingestion of adequate amounts of fluid, particularly with the bedtime dose, is recommended to reduce the risk of esophageal irritation and ulceration by tetracycline hydrochloride.</p>
<p>If a dose is missed, patients should continue the normal dosing schedule until medication is gone.  Patients should not take double doses. If more than 4 doses are missed, the prescriber should be contacted.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section_3"></a><a name="section-4"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Each PYLERA capsule contains 140 mg of bismuth subcitrate potassium, 125 mg of metronidazole, and a smaller capsule inside containing 125 mg of tetracycline hydrochloride. The capsules are white and opaque, with the Axcan Pharma logo printed on the body and â€œBMTâ€? printed on the cap.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section_4"></a><a name="section-5"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section_4_1"></a><a name="section-5.1"></a><p></p>
<h2>4.1  Methoxyflurane</h2>
<p class="First">Do not administer methoxyflurane to patients taking PYLERA.  The concurrent use of tetracycline hydrochloride, a component of PYLERA, with methoxyflurane has been reported to result in fatal renal toxicity [See <span class="Italics">Drug Interactions <a href="#section_7">(7.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_4_2"></a><a name="section-5.2"></a><p></p>
<h2>4.2 Disulfiram</h2>
<p class="First">PYLERA is contraindicated in patients who have taken disulfiram within the last two weeks.  <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic reactions</span> have been reported in alcoholic patients who are using metronidazole, a component of PYLERA, and disulfiram concurrently [See <span class="Italics">Drug Interactions <a href="#section_7">(7.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_4_3"></a><a name="section-5.3"></a><p></p>
<h2>4.3 Alcohol</h2>
<p class="First">Alcoholic beverages or other products containing propylene glycol should not be consumed during and for at least 3 days after therapy with PYLERA.  A disulfiram-like reaction (abdomincal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>) may occur due to the interaction between alcohol or propylene glycol and metronidazole, a component of PYLERA [See <span class="Italics">Drug Interactions <a href="#section_7">(7.3</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_4_4"></a><a name="section-5.4"></a><p></p>
<h2>4.4 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First"> PYLERA is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.  The antianabolic action of the tetracyclines may cause an increase in blood urea nitrogen (BUN) [See <span class="Italics">Adverse Reactions <a href="#section_6">(6.3)</a>]</span>.  In patients with significantly <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, higher serum concentrations of tetracyclines may lead to <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>, and <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_4_5"></a><a name="section-5.5"></a><p></p>
<h2>4.5 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First"> PYLERA is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g. <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) to bismuth subcitrate potassium, metronidazole or other nitroimidazole derivatives, or tetracycline [See <span class="Italics">Adverse Reactions <a href="#section_6">(6.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section_5"></a><a name="section-6"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5_1"></a><a name="section-6.1"></a><p></p>
<h2>5.1 Fetal Toxicity</h2>
<p class="First">There are no adequate and well-controlled studies of PYLERA in pregnant women.  However, tetracycline can cause fetal harm when administered to a pregnant women.  The use of drugs of the tetracycline class during the second and third trimester pregnancy can also cause permanent discoloration of the teeth (yellow-gray brown) and possibly inhibit bone development [See <span class="Italics">Warnings and Precautions <a href="#section_5">(5.3)</a>]</span>.  Administration of oral tetracycline to pregnant rats at various doses resulted in yellow fluorescence in teeth and bones in newborn animals.  If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus [See <span class="Italics">Use in Specific Populations <a href="#section_8">(8.1)</a>]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5_2"></a><a name="section-6.2"></a><p></p>
<h2>5.2	Maternal Toxicity</h2>
<p class="First">
									Tetracycline administered during pregnancy at high doses (&gt; 2 g IV) was associated with rare but serious cases of maternal hepatotoxicity.  This syndrome may result in stillborn or <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">premature birth</span> due to maternal pathology [See <span class="Italics">Use in Specific Populations <a href="#section_8">(8.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5_3"></a><a name="section-6.3"></a><p></p>
<h2>5.3	Tooth Enamel Discoloration and Hypoplasia</h2>
<p class="First">The use of drugs of the tetracycline class during tooth development (last half of pregnancy, infancy, and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray brown).  This adverse reaction is more commom during long-term use of the drug, but has been observed following repeated short-courses.  <span class="product-label-link" type="condition" conceptid="4131814" conceptname="Enamel hypoplasia">Enamel hypoplasia</span> has also been reported.  PYLERA, therefore, should not be used in this age group unless other drugs are not likely to be effective or are contraindicated [See <span class="Italics">Use in Specific Populations <a href="#section_8">(8.4)</a>]</span>
.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5_4"></a><a name="section-6.4"></a><p></p>
<h2>5.4	Central and Peripheral Nervous System Effects</h2>
<p class="First">Metronidazole: Cases of <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> (including <span class="product-label-link" type="condition" conceptid="380410" conceptname="Nutritional optic neuropathy">optic neuropathy</span>) have been reported with metronidazole: <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span> has been reported in association with cerebellar toxicity characterized by <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>.  CNS lesions seen on MRI have been described in reports of <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>.  CNS symptoms are generally reversible within days to weeks upon discontinuation of metronidazole.  CNS lesions seen on MRI have also been described as reversible; <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>, mainly of sensory type has been reported and is characterized by <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> of an extremity.  </p>
<p><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsive seizures</span> have been reported in patients treated with metronidazole.</p>
<p><span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic meningitis</span>: Cases of <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span> have been reported with metronidazole.  Symptoms can occur within hours of dose adiminstration and generally resolve after metronidazole therapy is discontinued.  </p>
<p>Tetracycline: Cases of <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span> in adults have been associated with the use of tetracycline.  The usual clinical manifestations are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>.  While this condition and related symptoms usually resolve soon after discontinuation of the tetracycline, the possibility for permanent sequelae exists.  </p>
<p>Bismuth-containing products: Cases of <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> associated with excessive doses of various bismuth-containing products have been reported.  Effects have been reversible with discontinuation of bismuth therapy.  </p>
<p>The appearance of abnormal neurologic signs and symptoms demands the prompt evaluation of the benefit/risk ratio of the continuation of PYLERA therapy [See <span class="Italics">Adverse Reactions <a href="#section_6">(6.3)</a>]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5_5"></a><a name="section-6.5"></a><p></p>
<h2>5.5	Development of <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">Superinfections</span></h2>
<p class="First">Known or previously unrecognized <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span> may present more prominent symptoms during therapy with metronidazole and requires treatment with an antifungal agent.</p>
<p>As with other antibiotics, use of tetracycline hydrochloride may result in overgrowth of nonsusceptible organisms, including fungi.  If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, discontinue PYLERA and institute appropriate therapy</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5_6"></a><a name="section-6.6"></a><p></p>
<h2>5.6	<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span></h2>
<p class="First">
									<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span>, manifested by an exaggerated sunburn reaction, has been observed in patients taking tetracycline [See <span class="Italics">Adverse Reactions <a href="#section_6">(6.3)</a>]</span>.  Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs.  Instruct patients taking PYLERA to avoid exposure to the sun or sun lamps.  Discontinue treatment at the first evidence of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">skin erythema</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5_7"></a><a name="section-6.7"></a><p></p>
<h2>5.7	Darkening of the Tongue and/or Black Stool</h2>
<p class="First">Bismuth subcitrate potassium may cause temporary and harmless darkening of the tongue and/or black stool, generally reversible within several days after treatment is stopped [See <span class="Italics">Adverse Reactions <a href="#section_6">(6.1)</a>]</span>.  Stool darkening should not be <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span> with <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5_8"></a><a name="section-6.8"></a><p></p>
<h2>5.8	Use in Patients with <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood Dyscrasias</span></h2>
<p class="First">Metronidazole is a nitroimidazole, and should be used with care in patients with evidence or history of <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasia</span>.  A mild <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> has been observed during its administration; however, no persistent hematologic abnormalities attributable to metronidazole have been observed in clinical studies.  Total and differential leukocyte counts are recommended before and after therapy [See <span class="Italics">Adverse Reactions <a href="#section_6">(6.3)</a>]</span>.  </p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section_5_9"></a><a name="section-6.9"></a><p></p>
<h2>5.9	Laboratory Test Interactions</h2>
<p class="First">Bismuth absorbs x-rays and may interfere with x-ray diagnostic procedures of the gastrointestinal tract.</p>
<p>Bismuth subcitrate potassium may cause a temporary and harmless darkening of the stool.  However, this change does not interfere with standard tests for occult blood.</p>
<p>Metronizadole may interfere with certain types of determinations of serum chemistry values, such as <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (AST, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>), <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT, SGPT), lactate dehydrogenase (LDH), triglycerides, and hexokinase glucose.  Values of zero may be observed.  All of the assays in which interference has been reported involve enzymatic coupling of the assay to oxidation-reduction of nicotinamide (NAD+ &lt;=&gt; NADH). Interference is due to the similarity in absorbance peaks of NADH (340 nm) and metronidazole (322 nm) at pH 7</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5_10"></a><a name="section-6.10"></a><p></p>
<h2>5.10	Development of Drug Resistant Bacteria</h2>
<p class="First">Prescribing PYLERA in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section_6"></a><a name="section-7"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<br><div class="Section" data-sectionCode="42229-5">
<a name="section_6_1"></a><a name="section-7.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The safety of PYLERA plus omeprazole (OBMT) to eradicate <span class="Italics">Helicobacter pylori</span> was assessed in an open-label, randomized, active-controlled clinical trial conducted in North America.  The duration of treatment was 10 days with 147 patients exposed to PYLERA plus omeprazole (OBMT) and 152 exposed to control, consisting of omeprazole, amoxicillin, and clarithromycin (OAC).  The age of the population in the study ranged from 18 to 75 years, with 59% male patients and 59% Caucasian patients.</p>
<p>Adverse drug reactions were reported in 58% of patients in the OBMT group and 59% of patients in the OAC group.  There were no adverse reactions leading to discontinuation of the study during the clinical trial. </p>
<p>Adverse reactions with an incidence of â‰¥ 5% in OBMT group include <span class="product-label-link" type="condition" conceptid="437671" conceptname="Abnormal feces">abnormal feces</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. Adverse drug reactions with an incidence of â‰¥ 5% in OAC group include <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<p><span class="Bold">Table 2 </span>lists adverse reactions with an incidence of â‰¥ 1%, in either groups (OBMT vs OAC) and in order of decreasing incidence for the OBMT group.</p>
<br><a name="table2"></a><table frame="box" width="100%">
<caption><span>Table 2: Adverse reactions with an incidence of â‰¥ 1% from North American trial, [n (%)]</span></caption>
<colgroup>
<col align="left">
<col align="center">
<col align="center">
</colgroup>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>OBMT = Omeprazole + PYLERA</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">â€ </a></dt>
<dd>OAC = Omeprazole + Amoxicillin + Clarithromycin;</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">â€¡</a></dt>
<dd>Dark stools [See <span class="Italics">Warnings and Precautions <a href="#section_5">(5.7)</a>].</span>
</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td align="left"><span class="Bold">Preferred Term </span></td>
<td align="center"><span class="Bold">OBMT<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> (n = 147) </span></td>
<td align="center"><span class="Bold">OAC<a name="footnote-reference-2" href="#footnote-2" class="Sup">â€ </a> (n = 152) </span></td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold Underline"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td></tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="437671" conceptname="Abnormal feces">Abnormal feces</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">â€¡</a>
</td>
<td align="center">23 (15.6%) </td>
<td align="center">7 (4.6%) </td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td align="center">12 (8.2%) </td>
<td align="center">14 (9.2%) </td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td align="center">10 (6.8%) </td>
<td align="center">20 (13.2%) </td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td align="center">7 (4.8%) </td>
<td align="center">2 (1.3%) </td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> </td>
<td align="center">4 (2.7%) </td>
<td align="center">10 (6.6%) </td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center">2 (1.4%)</td>
<td align="center">5 (3.3%)</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span> </td>
<td align="center">2 (1.4%) </td>
<td align="center">1 (0.7%) </td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td align="center">0 </td>
<td align="center">4 (2.6%) </td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">Glossitis</span></td>
<td align="center">0 </td>
<td align="center">2 (1.3%) </td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold Underline">General disorders and administration site conditions</span></td></tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center">5 (3.4%) </td>
<td align="center">2 (1.3%) </td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold Underline"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></td></tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginal infection</span></td>
<td align="center">4 (2.7%) </td>
<td align="center">3 (2.0%) </td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold Underline"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td></tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </td>
<td align="center">8 (5.4%) </td>
<td align="center">8 (5.3%) </td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span></td>
<td align="center">6 (4.1%) </td>
<td align="center">18 (11.8%) </td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">4 (2.7%) </td>
<td align="center">4 (2.6%) </td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold Underline">Investigations</span></td></tr>
<tr>
<td align="left">Laboratory test abnormal</td>
<td align="center">3 (2.0%) </td>
<td align="center">4 (2.6%) </td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">Alanine aminotransferase</span> increased</td>
<td align="center">2 (1.4%) </td>
<td align="center">0 </td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">Aspartate aminotransferase</span> increased</td>
<td align="center">2 (1.4%) </td>
<td align="center">0 </td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold Underline">Renal and urinary disorders</span></td></tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4298419" conceptname="Cloudy urine">Urine abnormality</span></td>
<td align="center">2 (1.4%) </td>
<td align="center">0 </td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold Underline">Skin and subcutaneous tissue disorders</span></td></tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> Maculo-Papular </td>
<td align="center">2 (1.4%) </td>
<td align="center">0 </td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center">1 (0.7%) </td>
<td align="center">3 (2.0%) </td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td align="center">0 </td>
<td align="center">4 (2.6%) </td>
</tr>
</tbody>
</table>
<p>Adverse reactions with an incidence of &lt;1% for OBMT group are: <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, tongue darkening [See <span class="Italics">Warnings and Precautions <a href="#section_5">(5.7)</a>].</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="4294804" conceptname="Creatine kinase">blood creatine phosphokinase</span> increased, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_6_2"></a><a name="section-7.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">Additionally, the following adverse reactions, presented by system organ class in alphabetical order, have been identified during post approval use of PYLERA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<ul>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span>: abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span></li>
<li>
<span class="Italics">General disorders and administration site conditions</span>: <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>.</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span>: <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_6_3"></a><a name="section-7.3"></a><p></p>
<h2>6.3	Other Important Adverse Reactions from Labeling for the Individual Components of PYLERA</h2>
<p class="First"><span class="Underline">Metronidazole</span></p>
<p><span class="Italics">Blood and Lymphatic system disorders:</span>  reversible <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, (<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leucopenia</span>) in cases of prolonged treatment; rarely reversible <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> however no persistent haematological abnormalities attributable to metronidazole have been observed [See <span class="Italics">Warnings and Precautions <a href="#section_5">(5.4)</a>]</span>.
								</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>:</span> Flattening of the T-wave may be seen in electrocardiographic tracings.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:</span> Furry tongue, glositis, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>; these may be associated with a sudden overgrowth of <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candida</span> which may occur during therapy[See <span class="Italics">Warnings and Precautions <a href="#section_5">(5.1)</a>]</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, Stevens - Johnson syndrome, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> [See <span class="Italics">Contraindications <a href="#section_4">(4.5)</a>]</span>.
								</p>
<p><span class="Italics">Metabolism and nutrition disorders: </span> Cases of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> have been reported, which abated on withdrawal of the drug, have been reported.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>: </span> The most serious adverse reactions reported in patients treated with metronidazole have been <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive seizures</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>, optic and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, the latter characterized mainly by <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> of an extremity.  In addition, patients have reported <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> [See <span class="Italics">Warnings and Precautions <a href="#section_5">(5.4)</a>]</span>.</p>
<p><span class="Underline">Tetracycline Hydrochloride</span></p>
<p><span class="Italics">Blood and lymphatic system disorders: </span> <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>: </span> Rare instances of <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> and <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulceration</span> have been reported in patients taking the tetracycline-class antibiotics in capsule and tablet form. Most of the patients who experienced esophageal irritation took the medication immediately before going to bed. Permanent discoloration of teeth may be caused when tetracycline is used during tooth development. <span class="product-label-link" type="condition" conceptid="4131814" conceptname="Enamel hypoplasia">Enamel hypoplasia</span> has also been reported [See <span class="Italics">Warnings and Precautions <a href="#section_5">(5.1)</a>].</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>: </span> <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">Pseudotumor cerebri</span> (<span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">benign intracranial hypertension</span>) in adults and bulging fontanels in infants. <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span> and <span class="product-label-link" type="condition" conceptid="4237155" conceptname="Eaton-Lambert syndrome">myasthenic syndrome</span> have been reported rarely.</p>
<p><span class="Italics">Renal and urinary disorders: </span> Rise in BUN has been reported and is possibly dose related [See <span class="Italics">Contraindications <a href="#section_4">(4.4)</a>]</span>.</p>
<p><span class="Italics">Skin and subcutaneous tissue disorders: </span> <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">Exfoliative dermatitis</span> and <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span> have been rarely reported [See <span class="Italics">Warnings and Precautions <a href="#section_5">(5.5)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section_7"></a><a name="section-8"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section_7_1"></a><a name="section-8.1"></a><p></p>
<h2>7.1	Methoxyflurane</h2>
<p class="First">Do not administer methoxyflurane to patients taking PYLERA.  The concurrent use of tetracycline hydrochloride, a component of PYLERA, with methoxyflurane has been reported to result in fatal renal toxicity [See <span class="Italics">Contraindications <a href="#section_4">(4.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_7_2"></a><a name="section-8.2"></a><p></p>
<h2>7.2	Disulfiram</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic reactions</span> have been reported in alcoholic patients who are using metronidazole, a component of PYLERA and disulfiram concurrently.  PYLERA should not be given to patients who have taken disulfiram within the last 2 weeks [See <span class="Italics">Contraindications <a href="#section_4">(4.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_7_3"></a><a name="section-8.3"></a><p></p>
<h2>7.3	Alcohol</h2>
<p class="First">Consumption of alcoholic beverages or administration of other products containing propylene glycol during treatment with PYLERA and for at least 3 days afterwards may cause a disulfiram-like reaction (<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>) due to the interaction between alcohol or propylene glycol and metronidazole, a component of PYLERA.  Discontinue alcoholic beverage or other products containing propylene glycol during and for at least 3 days after therapy with PYLERA [See <span class="Italics">Contraindications <a href="#section_4">(4.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_7_4"></a><a name="section-8.4"></a><p></p>
<h2>7.4	Oral Contraceptives</h2>
<p class="First">Concurrent use of PYLERA with oral contraceptive may make oral contraceptives less effective due to an interaction with the tetracycline component of PYLERA.  Breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> has been reported.  Women of child-bearing potential should use a different or additional form of contraception while taking PYLERA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_7_5"></a><a name="section-8.5"></a><p></p>
<h2>7.5	Anticoagulants</h2>
<p class="First">PYLERA may alter the anticoagulant effects of warfarin and other oral coumarin anticoagulants.  Metronidazole has been reported to potentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time.  Tetracycline has been shown to depress plasma <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> activity. <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time, International Normalized Ratio (INR), or other suitable anticoagulation tests should be closely monitored if PYLERA is administered concomitantly with warfarin. Patients should also be monitored for evidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_7_6"></a><a name="section-8.6"></a><p></p>
<h2>7.6	Lithium</h2>
<p class="First">In patients stabilized on relatively high doses of lithium, short-term use of PYLERA may cause elevation of serum lithium concentrations and signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> due to the interaction between metronidazole and lithium.  Serum lithium and serum creatinine concentrations should be monitored several days after beginning treatment with PYLERA to detect any increase that may precede clinical symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_7_7"></a><a name="section-8.7"></a><p></p>
<h2>7.7	Antacids, Multivitamins, or Dairy Products</h2>
<p class="First">The absorption of PYLERA may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>; or milk or dairy products due to the interaction between these products and tetracycline.  These products should not be consumed concomitantly with PYLERA.  However, the clinical significance of reduced tetracycline systemic exposure is unknown as the relative contribution of systemic versus local antimicrobial activity against <span class="Italics">Helicobacter pylori</span> has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_7_8"></a><a name="section-8.8"></a><p></p>
<h2>7.8	Penicillin</h2>
<p class="First">Bacteriostatic drugs, such as the tetracycline class of antibiotics, may interfere with the bactericidal action of penicillin; therefore, penicillin should not be used concomitantly with PYLERA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_7_9"></a><a name="section-8.9"></a><p></p>
<h2>7.9	Inhibitors of CYP450 liver enzymes</h2>
<p class="First">The simultaneous administration of PYLERA and drugs that inhibit microsomal liver enzymes, such as cimetidine, may result in a prolonged half-life and decreased plasma clearance of metronidazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_7_10"></a><a name="section-8.10"></a><p></p>
<h2>7.10	Inducers of CYP450 liver enzymes</h2>
<p class="First">The simultaneous administration of PYLERA and drugs that induce microsomal liver enzymes, such as phenytoin or phenobarbital, may accelerate the elimination of metronidazole, resulting in reduced plasma concentrations of metronidazole.  Impaired clearance of phenytoin has also been reported in this situation. Monitor phenytoin concentrations during treatment with PYLERA.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section_8"></a><a name="section-9"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="section_8_1"></a><a name="section-9.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category D</span> [See <span class="Italics">Warnings and Precautions <a href="#section_5">(5.1)</a>]</span></p>
<p>PYLERA contains bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride.  There are no adequate and well-controlled studies of Pylera in pregnant women.  However, tetracycline can cause fetal harm when administered to a pregnant woman.   The use of tetracycline during the second and third trimester pregnancy can cause permanent discoloration of the teeth (yellow-gray brown) and possibly inhibit bone development. Administration of oral tetracycline to pregnant animals at various doses resulted in yellow fluorescence in teeth and bones.  If PYLERA is used during pregnancy, or if the patient becomes pregnant while taking PYLERA, the patient should be apprised of the potential hazard to the fetus.  </p>
<p>The available human and animal data are summarized below for each of PYLERA's active ingredients:</p>
<p><span class="Underline">Tetracycline</span></p>
<p>Published case reports have described the yellowing of bones and teeth in human infants exposed to tetracycline during the second and third trimester of pregnancy.  The yellowing is caused by the direct deposition of tetracycline during the mineralization process.  The discoloration is more common during long-term use of the drug but has also been observed following repeated short-term courses.  All tetracyclines form a stable calcium complex in any bone forming tissue.  A decrease in fibula growth rate was observed in premature infants given oral tetracycline in doses of 25 mg/kg every six hours.  The effect resolved when the drug was discontinuted.  One long-term follow-up study in children exposed to tetracycline in-utero showed no adverse effects on bone growth and development.</p>
<p>Tetracycline administered during pregnancy at high doses (&gt; 2 g IV) was associated with rare but serious cases of maternal hepatotoxicity.  This syndrome may result in stillborn or <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">premature birth</span> due to maternal pathology [See <span class="Italics">Warnings and Precautions <a href="#section_5">(5.2)</a>]</span></p>
<p>Results of animal studies indicate that tetracycline crosses the placenta, is found in fetal tissues, and can have toxic effects on the developing fetus (often related to reversible retardation of skeletal development).  Evidence of embryotoxicity has also been noted in animals treated early in pregnancy.  Multiple studies of limited design were conducted with pregnant and lactating female rats that resulted in fetuses and neonates with yellow discoloration of bones and teeth.</p>
<p><span class="Underline">Metronidazole</span></p>
<p>There are published data from case-control studies, cohort studies, and 2 meta-analyses that include more than 5000 pregnant women who used metronidazole during pregnancy.  Many studies included first trimester exposures.  One study showed an increased risk of <span class="product-label-link" type="condition" conceptid="133861" conceptname="Cleft lip">cleft lip</span>, with or without <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, in infants exposed to metronidazole in-utero; however, these findings were not confirmed.  In additon, more than ten randomized, placebo-controlled clinical trials enrolled more than 5000 pregnant women to assess the use of antibiotic treatment (including metronidazole) for <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> on the incidence of preterm delivery.  Most studies did not show an increased risk for congenital anomalies or other adverse fetal outcomes following metronidazole exposure during pregnancy.  These studies conducted to assess the risk of infant cancer following metronidazole exposure during pregnancy did not show an increased risk; however, the ability of these studies to detect such a signal was limited.</p>
<p>Metronidazole crosses the placental barrier and its effects on the human fetal organogenesis are not known.  No fetotoxicity was observed when metronidazole was administered orally to pregnant mice at 10 mg/kg/day, approximately 5 percent of the indicated human dose (1500 mg/day) based on body surface area; however in a single small study where the drug was administered intraperitoneally, some intrauterine <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were observed.  The relationship of these findings to the drug is unknown.</p>
<p><span class="Underline">Bismuth subcitrate potassium</span></p>
<p>Animal reproductive studies have not been conducted with bismuth subcitrate potassium.  It is also not known whether bismuth subcitrate potassium can cause fetal harm when administered to a pregnant women or can affect reproduction capacity.	</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section_8_3"></a><a name="section-9.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">PYLERA contains bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride.  Metronidazole is present in human milk at concentrations similar to maternal serum levels, and infant serum levels can be close to or comparable to infant therapeutic levels.  Because of the potential for tumorigenicity shown for metronidazole in animal studies, a decision should be made whether to discontinue nursing or to discontinue metronidazole, taking into account the importance of the therapy to the mother.  Alternatively, a nursing mother may choose to pump and discard human milk for the duration of PYLERA therapy, and for 24 hours after therapy ends and feed her infant stored human milk or formula.</p>
<p>Tetracycline is present in human milk at concentrations similar to maternal serum levels; however, it binds with calcium in human milk.  Data indicate that oral absorption of tetracycline in infants is low due to the calcium binding in human milk.  It is not known whether bismuth subcitrate potassium is excreted in human milk.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section_8_4"></a><a name="section-9.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of PYLERA in pediatric patients infected with <span class="Italics">Helicobacter pylori</span> have not been established.</p>
<p>Tetracycline use in children may cause permanent discoloration of the teeth. <span class="product-label-link" type="condition" conceptid="4131814" conceptname="Enamel hypoplasia">Enamel hypoplasia</span> has also been reported.  PYLERA should not be used in children up to 8 years of age [See <span class="Italics">Warnings and Precautions <a href="#section_5"> (5.3)</a>]</span>.
								</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section_8_5"></a><a name="section-9.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First"> Of the 324 patients who received PYLERA in clinical studies, 40 were â‰¥ 65 years old.  Clinical studies of PYLERA did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger patients.  Other reported clinical experience has not identified differences in responses between the elderly and younger patients.  In general, elderly patients may have a  greater frequency of decreased hepatic, renal, or cardiac function, and concomitant diseases or other drug therapies.  Bismuth subcitrate potassium, a component of PYLERA, is known to be substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.  Because elderly patients are more likely to have decreased renal function, additional monitoring may be required <span class="Italics">[See Contraindications <a href="#section_4">(4.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_8_6"></a><a name="section-9.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The antianabolic action of the tetracyclines may cause an increase in blood urea nitrogen (BUN).  While this is not a problem in those with normal renal function, in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, higher serum concentrations  of tetracycline may lead to <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>, and <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> <span class="Italics">[See Contraindications <a href="#section_4">(4.4)</a>]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_8_7"></a><a name="section-9.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> metabolize metronidazole slowly, with resultant accumulation of metronidazole and its metabolites in plasma.   Use PYLERA with caution in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.  </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section_10"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">In case of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, patients should contact a physician, poison control center, or emergency room.  There is neither a pharmacological basis nor data suggesting an increased toxicity of the combination compared to individual components.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section_11"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">PYLERA capsules are a combination antimicrobial product containing bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride for oral administration. Each size 0 elongated capsule contains:<br></p>
<ul>
<li>bismuth subcitrate potassium, 140 mg</li>
<li>metronidazole, 125 mg</li>
<li>smaller capsule (size 3) containing tetracycline hydrochloride, 125 mg</li>
</ul>
<p>Tetracycline hydrochloride is encapsulated within a smaller capsule to create a barrier to avoid contact with bismuth subcitrate potassium.</p>
<p>Each PYLERA capsule contains the following inactive ingredients: Magnesium Stearate NF, Lactose Monohydrate NF, Talc USP, Gelatin USP, and Titanium Dioxide NF. Printed in red ink.</p>
<p>Bismuth subcitrate potassium is a white or almost white powder. It is a soluble, complex bismuth salt of citric acid. The schematized empirical molecular formula of bismuth subcitrate potassium is Bi (Citrate)<span class="Sub">2</span>K<span class="Sub">5</span>â—?3 H<span class="Sub">2</span>O. The equivalent theoretical molecular formula is BiC<span class="Sub">12</span>H<span class="Sub">14</span>K<span class="Sub">5</span>O<span class="Sub">17</span>. The molecular <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> of the theoretical molecular formula of a single unit of bismuth subcitrate potassium is 834.71. </p>
<p>Metronidazole is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow crystalline powder. Metronidazole is 2-methyl-5-nitroimidazole-1-ethanol, with a molecular formula of C<span class="Sub">6</span>H<span class="Sub">9</span>N<span class="Sub">3</span>O<span class="Sub">3</span> and the following structural formula:</p>
<div class="Figure"><img alt="pylera-structure-metronidazole" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7fe5d2db-c59d-4e15-acd7-f9df8eca45aa&amp;name=pylera-structure-metronidazole.jpg"></div>
<p>Molecular weight: 171.2</p>
<p>Tetracycline hydrochloride is a yellow, odorless, crystalline powder. Tetracycline hydrochloride is stable in air, but exposure to strong sunlight causes it to darken. Tetracycline hydrochloride is (4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-penta-hydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrochloride, with a molecular formula of C<span class="Sub">22</span>H<span class="Sub">24</span>N<span class="Sub">2</span>O<span class="Sub">8</span>â—?HCl and the following structural formula:</p>
<div class="Figure"><img alt="pylera-structure-tetracycline" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7fe5d2db-c59d-4e15-acd7-f9df8eca45aa&amp;name=pylera-structure-tetracycline.jpg"></div>
<p>Molecular weight: 480.90 </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section_12"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section_12_1"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">PYLERA, a combination of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride is an antibacterial agent <span class="Italics">[See Clinical Pharmacology <a href="#section_12">(12.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section_12_3"></a><a name="section-12.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of the individual components of PYLERA, bismuth subcitrate potassium, metronidzole, tetracycline hydrochloride, are summarized below.  In addition, two studies on PYLERA were conducted to determine the effect of co-administration on the pharmacokinetics of the components.</p>
<br><p><span class="Underline">Bismuth Subcitrate Potassium (Bismuth) </span></p>
<p><span class="Italics">Absorption and Distribution</span></p>
<p>Orally absorbed bismuth is distributed throughout the entire body. Bismuth is highly bound to plasma proteins (&gt;90%).</p>
<p><span class="Italics">Metabolism and Excretion</span></p>
<p>The elimination half-life of bismuth is approximately 5 days in both blood and urine. Elimination of bismuth is primarily through urinary and biliary routes. The rate of renal elimination appears to reach steady state 2 weeks after treatment discontinuation with similar rates of elimination at 6 weeks after discontinuation. The average urinary elimination of bismuth is 2.6% per day in the first two weeks after discontinuation (urine drug concentrations 24 to 250 mcg/mL) suggesting tissue accumulation and slow elimination.</p>
<p><span class="Underline">Metronidazole </span></p>
<p><span class="Italics">Absorption and Distribution </span></p>
<p>Following oral administration, metronidazole is well absorbed, with peak plasma concentrations occurring between 1 and 2 hours after administration. Plasma concentrations of metronidazole are proportional to the administered dose, with oral administration of 500 mg producing a peak plasma concentration of 12 mcg/mL.</p>
<p>Metronidazole appears in the plasma mainly as unchanged compound with lesser quantities of the 2-hydroxymethyl metabolite also present. Less than 20% of the circulating metronidazole is bound to plasma proteins. Metronidazole also appears in cerebrospinal fluid, saliva, and breast milk in concentration similar to those found in plasma. </p>
<p><span class="Italics">Metabolism and Excretion </span></p>
<p>The average elimination half-life of metronidazole in normal volunteers is 8 hours. The major route of elimination of metronidazole and its metabolites is via the urine (60% to 80% of the dose), with fecal excretion accounting for 6% to 15% of the dose. The metabolites that appear in the urine result primarily from side-chain oxidation [1-(Î²-hydroxyethyl) 2-hydroxymethyl-5-nitroimidazole and 2-methyl-5-nitroimidazole-1-yl-acetic acid] and glucuronide conjugation, with unchanged metronidazole accounting for approximately 20% of the total. Renal clearance of metronidazole is approximately 10 mL/min/1.73m<span class="Sup">2</span>.</p>
<p>Decreased renal function does not alter the single dose pharmacokinetics of metronidazole. In patients with decreased liver function, plasma clearance of metronidazole is decreased. </p>
<p><span class="Underline">Tetracycline Hydrochloride </span></p>
<p><span class="Italics">Absorption, Distribution, Metabolism and Excretion </span></p>
<p>Tetracycline hydrochloride is absorbed (60%-90%) in the stomach and upper small intestine. The presence of food, milk or cations may significantly decrease the extent of absorption. In the plasma, tetracycline is bound to plasma proteins in varying degrees. It is concentrated by the liver in the bile and excreted in the urine and feces at high concentrations in biologically active form.</p>
<p>Tetracycline hydrochloride is distributed into most body tissues and fluids. It is distributed into the bile and undergoes varying degrees of enterohepatic recirculation. Tetracycline hydrochloride tends to localize in tumors, necrotic or ischemic tissue, liver and spleen and form tetracycline-calcium orthophosphate complexes at sites of new bone formation or tooth development. Tetracycline readily crosses the placenta and is excreted in high amounts in breast milk.</p>
<p><span class="Underline">PYLERA Capsules </span></p>
<p>A comparative bioavailability study of metronidazole (375 mg), tetracycline hydrochloride (375 mg) and bismuth subcitrate potassium (420 mg, equivalent to 120 mg Bi<span class="Sub">2</span>O<span class="Sub">3</span>) administered as PYLERA or as 3 separate capsule formulations administered simultaneously was conducted in healthy male volunteers. The pharmacokinetic parameters for the individual drugs, when administered as separate capsule formulations or as PYLERA, are similar as shown in <span class="Bold">Table 3</span>. </p>
<a name="table3"></a><table frame="box" width="100%">
<caption><span>Table 3: Mean (%CV) Pharmacokinetic Parameters for Metronidazole, Tetracycline hydrochloride, and Bismuth Subcitrate Potassium in Healthy Volunteers (N=18)</span></caption>
<colgroup>
<col align="left">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
</colgroup>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>C.V. â€“ Coefficient Variation</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">â€ </a></dt>
<dd>PYLERA given as a single dose of 3 capsules</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td align="left"></td>
<td align="center"></td>
<td align="center">
<span class="Bold">C<span class="Sub">max</span></span><span class="Bold">(ng/mL) </span><span class="Bold">(%C.V.<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a>) </span>
</td>
<td align="center">
<span class="Bold">AUC<span class="Sub">T</span> (ng Â· h/mL) </span><span class="Bold">(%C.V.<a href="#footnote-4" class="Sup">*</a>) </span>
</td>
<td align="center">
<span class="Bold">AUC<span class="Sub">âˆž</span> (ng Â· h/mL) </span><span class="Bold">(%C.V.<a href="#footnote-4" class="Sup">*</a>) </span>
</td>
</tr>
<tr>
<td align="left"><span class="Bold">Metronidazole </span></td>
<td align="center">Metronidazole Capsule </td>
<td align="center">9044 (20) </td>
<td align="center">80289 (15) </td>
<td align="center">81849 (16) </td>
</tr>
<tr>
<td align="left"></td>
<td align="center">PYLERA<a name="footnote-reference-5" href="#footnote-5" class="Sup">â€ </a>
</td>
<td align="center">8666.3 (22) </td>
<td align="center">83018 (17) </td>
<td align="center">84413 (17) </td>
</tr>
<tr>
<td align="left"><span class="Bold">Tetracycline </span></td>
<td align="center">Tetracycline Capsules </td>
<td align="center">748.0 (40) </td>
<td align="center">9544 (55) </td>
<td align="center">9864 (53) </td>
</tr>
<tr>
<td align="left"></td>
<td align="center">PYLERA<a href="#footnote-5" class="Sup">â€ </a>
</td>
<td align="center">774 (47) </td>
<td align="center">9674 (50) </td>
<td align="center">9987 (49) </td>
</tr>
<tr>
<td align="left"><span class="Bold">Bismuth </span></td>
<td align="center">Bismuth Capsule </td>
<td align="center">22 (123) </td>
<td align="center">47 (129) </td>
<td align="center">65.4 (113) </td>
</tr>
<tr class="Last">
<td align="left"></td>
<td align="center">PYLERA<a href="#footnote-5" class="Sup">â€ </a>
</td>
<td align="center">17 (202) </td>
<td align="center">43 (191) </td>
<td align="center">57 (178) </td>
</tr>
</tbody>
</table>
<p><span class="Underline">Effect of Bismuth on the Bioavailability of Tetracycline Hydrochloride </span></p>
<p>There is an anticipated reduction in tetracycline hydrochloride systemic absorption due to an interaction with bismuth.  The effect of a reduced tetracycline hydrochloride systemic exposure, due to an interaction with bismuth, on the clinical efficacy of PYLERA is not thought to be clinically meaningful as the contribution of systemic, as compared to local, antimicrobial activity against <span class="Italics">Helicobacter pylori</span> has not been established. </p>
<p><span class="Underline">Effect of Food on the Bioavailability of PYLERA </span></p>
<p>The pharmacokinetic parameters for metronidazole, tetracycline hydrochloride and bismuth were also determined when PYLERA was administered under fasting and fed conditions, as shown in <span class="Bold">Table 4</span>.  Food reduced the systemic absorption of all three PYLERA components, with AUC values for metronidazole, tetracycline hydrochloride and bismuth being reduced by 6%, 34% and 60%, respectively. Reduction in the absorption of all three PYLERA components in the presence of food is not considered to be clinically significant. PYLERA should be given after meals and at bedtime, in combination with omeprazole twice a day.</p>
<a name="table4"></a><table frame="box" width="100%">
<caption><span>Table 4: Mean PYLERA Pharmacokinetic Parameters in Fasted and Fed States (N=18)<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a></span></caption>
<colgroup>
<col align="left">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
</colgroup>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>PYLERA given as a single dose of 3 capsules</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">â€ </a></dt>
<dd>T<span class="Sub">max</span> is expressed as median (range)</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td align="left"></td>
<td align="center" colspan="3"><span class="Bold">FED</span></td>
<td align="center" colspan="3"><span class="Bold">FASTED </span></td>
</tr>
<tr>
<td align="left"></td>
<td align="center"><span class="Bold">metronidazole</span></td>
<td align="center"><span class="Bold">tetracycline</span></td>
<td align="center"><span class="Bold">bismuth</span></td>
<td align="center"><span class="Bold">metronidazole</span></td>
<td align="center"><span class="Bold">tetracycline</span></td>
<td align="center"><span class="Bold">bismuth</span></td>
</tr>
<tr>
<td align="left">
<span class="Bold">C<span class="Sub">max</span> (ng/mL)</span><span class="Bold">(%C.V.) </span>
</td>
<td align="center">6835.0<br>(13)</td>
<td align="center">515.8<br>(36)</td>
<td align="center">1.7<br>(61)</td>
<td align="center">8666.3<br>(22)</td>
<td align="center">773.8<br>(47)</td>
<td align="center">16.7<br>(202)</td>
</tr>
<tr>
<td align="left">
<span class="Bold">T<span class="Sub">max</span> (hours)<a name="footnote-reference-7" href="#footnote-7" class="Sup">â€ </a></span><span class="Bold">(range)</span>
</td>
<td align="center">3.0<br>(1.3 â€“ 4.0) </td>
<td align="center">4.0<br>(2.5 â€“ 5.0) </td>
<td align="center">3.5<br>(0.8 â€“ 6.0) </td>
<td align="center">0.75<br>(0.5 - 3.5) </td>
<td align="center">3.3<br>(1.3 â€“ 5.0) </td>
<td align="center">0.6<br>(0.5 â€“ 1.7) </td>
</tr>
<tr class="Last">
<td align="left">
<span class="Bold">AUC<span class="Sub">âˆž</span></span><span class="Bold">(ng Â· h/mL)</span><span class="Bold">(%C.V.)</span>
</td>
<td align="center">79225.6<br>(18) </td>
<td align="center">5840.1<br>(312) </td>
<td align="center">18.4<br>(116) </td>
<td align="center">84413.6<br>(17) </td>
<td align="center">9986.7<br>(49) </td>
<td align="center">56.5<br>(178) </td>
</tr>
</tbody>
</table>
<p><span class="Underline">Effect of Omeprazole on the Bioavailability of Bismuth</span></p>
<p>The effect of omeprazole on bismuth absorption was assessed in 34 healthy volunteers given PYLERA (four times daily) with or without omeprazole (20 mg twice daily) for 6 days. In the presence of omeprazole, the extent of absorption of bismuth from PYLERA was significantly increased, compared to when no omeprazole was given (<span class="Bold">Table 5</span>). Concentration-dependent <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> is associated with long-term use of bismuth and not likely to occur with short-term administration or at steady state concentrations below 50 ng/mL. One subject transiently achieved a maximum bismuth concentration (C<span class="Sub">max</span>) higher than 50 ng/mL (73 ng/mL) following multiple dosing of PYLERA with omeprazole. The patient did not exhibit symptoms of <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> during the study. There is no clinical evidence to suggest that short-term exposure to bismuth C<span class="Sub">max</span> concentrations above 50Â ng/mL is associated with <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>.</p>
<br><a name="table5"></a><table frame="box" width="100%">
<caption><span>Table 5: Mean Bismuth Pharmacokinetic Parameters following PYLERA Administration<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a> With and Without Omeprazole (N=34)</span></caption>
<colgroup>
<col align="left">
<col align="left">
<col align="left">
<col align="left">
<col align="left">
</colgroup>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>PYLERA given as 3 capsules four times daily for 6 days with or without 20 mg omeprazole twice daily</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">â€ </a></dt>
<dd>C.V. â€“ Coefficient Variation</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td align="left" rowspan="2"><span class="Bold">Parameter</span></td>
<td align="left" colspan="2"><span class="Bold">Without omeprazole</span></td>
<td align="left" colspan="2"><span class="Bold">With omeprazole</span></td>
</tr>
<tr>
<td align="left"><span class="Bold">Mean</span></td>
<td align="left"><span class="Bold">%C.V.<a name="footnote-reference-9" href="#footnote-9" class="Sup">â€ </a></span></td>
<td align="left"><span class="Bold">Mean</span></td>
<td align="left"><span class="Bold">%C.V.<a href="#footnote-9" class="Sup">â€ </a></span></td>
</tr>
<tr>
<td align="left"><span class="Bold">C<span class="Sub">max</span>(ng/mL)</span></td>
<td align="left">8.1</td>
<td align="left">84</td>
<td align="left">25.5</td>
<td align="left">69</td>
</tr>
<tr class="Last">
<td align="left"><span class="Bold">AUC<span class="Sub">T</span>(ng Â· h/mL)</span></td>
<td align="left">48.5</td>
<td align="left">28</td>
<td align="left">140.9</td>
<td align="left">42</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_12_4"></a><a name="section-12.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First"><span class="Underline">Mechanism of Action</span></p>
<p>PYLERA, a combination of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride has antibacterial activity.  Metronidazole is metabolized through reductive pathways into reactive intermediates that have cytotoxic action. Tetracycline hydrochloride interacts with the 30S subunit of the bacterial ribosome and inhibits protein synthesis. The antibacterial action of bismuth salts is not well understood.</p>
<br><p><span class="Underline">Activity <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span></span></p>
<p>PYLERA plus omeprazole therapy has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Helicobacter pylori</span> both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. [See <span class="Italics">Clinical Studies<a href="#section_14"> (14)</a>]</span>.</p>
<p><span class="Underline">Susceptibility Test Methods</span></p>
<p><span class="Italics">Dilution techniques:</span></p>
<p>Susceptibility testing of <span class="Italics">Helicobacter pylori</span> isolates was performed for metronidazole using agar dilution methodology according to CLSI<span class="Sup">1</span> guidelines [See <span class="Italics">References<a href="#section_15"> (15)</a>]</span>, and <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs) were determined. </p>
<p>
Susceptibility testing of <span class="Italics">Helicobacter pylori</span> for metronidazole has not been standardized. No interpretive criteria have been established for testing metronidazole against <span class="Italics">H. pylori</span>. 
</p>
<p>
The clinical significance of metronidazole MIC values against <span class="Italics">H. pylori</span> is unknown. In the North American study, pre-treatment metronidazole MIC values showed no correlation with clinical outcome in patients treated with PYLERA and omeprazole therapy.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section_13"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section_13_1"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"> No long-term studies have been performed to evaluate the effect of PYLERA on carcinogenesis, mutagenesis, or impairment of fertility.</p>
<p><span class="Underline">Bismuth Subcitrate Potassium </span></p>
<p>No carcinogenicity or reproductive toxicity studies have been conducted with bismuth subcitrate potassium. Bismuth subsalicylate did not show mutagenic potential in the NTP <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> </span>plate assay. </p>
<br><p><span class="Underline">Metronidazole </span></p>
<p>Metronidazole has shown evidence of carcinogenic activity in a number of studies involving chronic, oral administration in mice and rats. Prominent among the effects in the mouse was an increased incidence of pulmonary tumorigenesis. This has been observed in all six reported studies in that species, including one study in which the animals were dosed on an intermittent schedule (administration during every fourth week only). At the highest dose levels, (approximately 500 mg/kg/day, which is approximately 1.6 times the indicated human dose for a 60 kg adult based on body surface area), there was a statistically significant increase in the incidence of <span class="product-label-link" type="condition" conceptid="201519" conceptname="Primary malignant neoplasm of liver">malignant liver tumors</span> in male mice. Also, the published results of one of the mouse studies indicate an increase in the incidence of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">malignant lymphomas</span> as well as pulmonary neoplasms associated with lifetime feeding of the drug. All these effects are statistically significant. Long-term, oral-dosing studies in the rat showed statistically significant increases in the incidence of various neoplasms, particularly in mammary and hepatic tumors, among female rats administered metronidazole over those noted in the concurrent female control groups. Two lifetime tumorigenicity studies in hamsters have been performed and reported to be negative. Although metronidazole has shown mutagenic activity in a number of <span class="Italics">in vitro</span> assay systems, studies in mammals (<span class="Italics">in vivo</span>) have failed to demonstrate a potential for genetic damage. </p>
<p>Fertility studies have been conducted with male rates and mice with divergent results.  Metronidazole, at doses up to 400 mg/kg/day (approximately 3 times the indicated human dose based on mg/m<span class="Sup">2</span>) for 28 days, failed to produce any adverse effects on fertility and testicular function in male rats. In another study where rats were treated with up to 400 mg/kg/day for 8 weeks, there was severe degeneration of the seminiferous epithelium in the testes which was associated with a marked decrease in testicular spermatid counts and epididymal sperm counts and a marked decrease in fecundity.  These effects were partially reversible.
</p>
<p>Fertility studies were performed in male mice at doses up to six times the maximum human dose based upon mg/m<span class="Sup">2</span> and have revealed no evidence of impaired fertility.  Another fertility study was performed in male mice at oral doses of 500 mg/kg/day (approximately 2 times the indicated human dose based on mg/m<span class="Sup">2</span> for 14 days.  Metronidazole significantly decreased testes and epididymides weight, decreased sperm viability, and increased the incidence of abnormal sperm.  The viability of sperm was normal by 2 months after the start of the treatment. </p>
<p><span class="Underline">Tetracycline hydrochloride </span></p>
<p>There has been no evidence of carcinogenicity for tetracycline hydrochloride in studies conducted with rats and mice. Some related antibiotics (oxytetracycline, minocycline) have shown evidence of oncogenic activity in rats. </p>
<p>There was evidence of mutagenicity by tetracycline hydrochloride in two <span class="Italics">in vitro</span> mammalian cell assay systems (L51784y mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> and Chinese hamster lung cells).</p>
<br><p>Tetracycline hydrochloride had no effect on fertility when administered in the diet to male and female rats at a daily intake of 25 times the human dose.</p>
<br>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section_14"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section_14_1"></a><a name="section-14.1"></a><p></p>
<h2>14.1 Eradication of <span class="Italics">Helicobacter pylori</span> in Patients with Active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> or History of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Disease 
</h2>
<p class="First">An open-label, parallel group, active-controlled, multicenter study in <span class="Italics">Helicobacter pylori</span> positive patients with current <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> or a history of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> disease was conducted in the United States and Canada (the North American Study). </p>
<p>Patients were randomized to one of the following 10-day treatment regimens: </p>
<ul>
<li>Three (3) PYLERA capsules four times daily, after meals and at bedtime plus 20 mg omeprazole twice a day after the morning and evening meals (OBMT).</li>
<li>Clarithromycin 500 mg plus 1000 mg amoxicillin plus 20 mg omeprazole twice a day before the morning and evening meals (OAC).</li>
</ul>
<p><span class="Italics">H. pylori</span> eradication rates, defined as two negative <span class="Sup">13</span>C-urea breath tests performed at 4 and 8 weeks post-therapy are shown in <span class="Bold">Table 6</span> for OBMT and OAC. The eradication rates for both groups were found to be similar using either the Per Protocol (PP) or Modified Intent-to-Treat (MITT) populations.</p>
<a name="table6"></a><table frame="box" width="100%">
<caption><span>Table 6: Helicobacter pylori Eradication at 8 Weeks after 10 Day Treatment Regimen Percent (%) of Patients Cured [95% Confidence Interval] (Number of Patients) </span></caption>
<colgroup>
<col align="left">
<col align="center">
<col align="center">
<col align="center">
</colgroup>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-10" href="#footnote-reference-10">*</a></dt>
<dd>
<span class="Bold">OBMT</span>: Omeprazole + PYLERA (bismuth subcitrate potassium / metronidazole / tetracycline hydrochloride)</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">â€ </a></dt>
<dd>
<span class="Bold">OAC</span>: Omeprazole + Amoxicillin + Clarithromycin</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">â€¡</a></dt>
<dd>Results for OAC treatment represent all isolates regardless of clarithromycin susceptibility. Eradication rates for clarithromycin susceptible organisms, as defined by an MIC â‰¤ 0.25 Î¼g/mL, were 94.6% and 92.1% for the PP and MITT analysis, respectively. Eradication rates for clarithromycin non-susceptible organisms, as defined by an MIC â‰¥ 0.5 Î¼g/mL, were 23.1% and 21.4% for the PP and MITT analysis, respectively.</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">Â§</a></dt>
<dd>Patients were included in the PP analysis if they had <span class="Italics">H. pylori </span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> documented at baseline, defined as a positive <span class="Sup">13</span>C-UBT plus histology or culture, had at least one endoscopically verified <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> â‰¥ 0.3 cm at baseline or had a documented history of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> disease, and were not protocol violators. Additionally, if patients dropped out of the study due to an adverse event related to the study drug, they were included in the evaluable analysis as failures of therapy.</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">Â¶</a></dt>
<dd>Patients were included in the MITT analysis if they had documented <span class="Italics">H. pylori </span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at baseline as defined above, and had at least one documented <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> at baseline or had a documented history of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> disease, and took at least one dose of study medication. All dropouts were included as failures of therapy.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td align="left"></td>
<td align="center" colspan="2"><span class="Bold">Treatment Group</span></td>
<td align="center"><span class="Bold">Difference </span></td>
</tr>
<tr>
<td align="left"></td>
<td align="center"><span class="Bold">OBMT<a name="footnote-reference-10" href="#footnote-10" class="Sup">*</a></span></td>
<td align="center">
<span class="Bold">OAC</span><a name="footnote-reference-11" href="#footnote-11" class="Sup">â€ </a><a name="footnote-reference-12" href="#footnote-12" class="Sup">â€¡</a>
</td>
<td align="center"></td>
</tr>
<tr>
<td align="left">Per Protocol<a name="footnote-reference-13" href="#footnote-13" class="Sup">Â§</a>
</td>
<td align="center">92.5%<br>[87.8, 97.2]<br>(n=120) </td>
<td align="center">85.7%<br>[76.9, 91.8]<br>(n=126) </td>
<td align="center">6.8<br>[-0.9, 14.5]</td>
</tr>
<tr class="Last">
<td align="left">Modified Intent-to-Treat<a name="footnote-reference-14" href="#footnote-14" class="Sup">Â¶</a>
</td>
<td align="center">87.7%<br> [82.2, 93.2]<br> (n=138) </td>
<td align="center">83.2%<br> [77.0, 89.5]<br> (n=137) </td>
<td align="center">4.5<br> [-3.9, 12.8] </td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section_15"></a><a name="section-15"></a><p></p>
<h1>15 REFERENCES</h1>
<ol><li>Clinical and Laboratory Standards Institute.  Methods <span class="Italics">for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically</span>; Approved Standard - - Eight edition.  Clinical and Laboratory standards Institute document M7-A8, Vol. 29, No. 2, CLSI, Wayne, PA, January 2009.</li></ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section_16"></a><a name="section-16"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">PYLERA is supplied as a white opaque capsule containing 140 mg bismuth subcitrate potassium, 125 mg metronidazole, and 125 mg tetracycline hydrochloride, with the Axcan Pharma logo printed on the body and â€œBMTâ€? printed on the cap. PYLERA is supplied in:</p>
<br><a name="iad68eb62-90bc-4bcc-839a-5383b53dca34"></a><table width="30%"><tbody class="Headless"><tr class="First Last">
<td>Bottles of 120<br>
</td>
<td>NDC 54868-6151-0<br>
</td>
</tr></tbody></table>
<br><p><span class="Underline">Storage</span></p>
<p>Store at controlled room temperature [68Â° to 77Â°F or 20Â° to 25Â°C]</p>
<br><p><br></p>
<br><p><br></p>
<p>Relabeling of "Additional Barcode" label by:</p>
<p>Physicians Total Care, Inc.</p>
<p>Tulsa, OKÂ Â Â Â Â Â Â  74146<br></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section_17"></a><a name="section-17"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section_17_1"></a><a name="section-17.1"></a><p></p>
<h2>17.1 Pregnant Women</h2>
<p class="First">Advise pregnant women that PYLERA capsules can cause fetal harm due to the tetracycline it contains.  Tetracycline use during the second and third trimesters of pregnancy can cause permanent discoloraton of the teeth (yellow-gray brown) and may inhibit bone development [See <span class="Italics">Warnings and Precautions <a href="#section_5">(5.1)</a>]</span> and [See <span class="Italics">Use in Specific Populations <a href="#section_8">(8.3)</a>]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_17_2"></a><a name="section-17.2"></a><p></p>
<h2>17.2 Human Milk Feeding</h2>
<p class="First">Advise women to avoid feeding their infants with their milk during PYLERA treatment.  Women should either discontinue feeding or pump and discard their milk during treatment and for 24 hours after the last dose [See <span class="Italics">Use in Specific Populations <a href="#section_8">(8.3)</a>]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_17_3"></a><a name="section-17.3"></a><p></p>
<h2>17.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">Inform patients that PYLERA may cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> and to discontinue PYLERA at the first sign of <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> [See <span class="Italics">Contraindications <a href="#section_4">(4.4)</a>]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_17_4"></a><a name="section-17.4"></a><p></p>
<h2>17.4 Central Nervous System Effects</h2>
<p class="First">Inform patients of the risk of central and peripheral nervous system effects with PYLERA and to discontinue PYLERA and report immediately to their health-care provider if any <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">neurologic symptoms</span> occur [See <span class="Italics">Warnings and Precautions <a href="#section_5">(5.4)</a>]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_17_5"></a><a name="section-17.5"></a><p></p>
<h2>17.5 <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span></h2>
<p class="First">Avoid exposure to sun or sun lamps while taking PYLERA<span class="Italics"> [See Warnings and Precautions <a href="#section_5">(5.6)</a>]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_17_6"></a><a name="section-17.6"></a><p></p>
<h2>17.6 Drug Interactions</h2>
<p class="First">Advise patients to report to their health-care provider the use of any other medications while taking PYLERA.  The administration of any of the following drugs with PYLERA may result in clinically significant adverse reactions or insufficient drug efficacies [See <span class="Italics">Contraindications <a href="#section_4">(4)</a>]</span> ;<span class="Italics">Drug Interactions <a href="#section_7">(7)</a>]</span> :</p>
<ul>
<li>Methoxyflurane</li>
<li>Disulfiram</li>
<li>Alcoholic Beverages, or Products Containing Propylene Glycol</li>
<li>Oral Contraceptives</li>
<li>Anticoagulants</li>
<li>Lithium</li>
<li>Antacids, Multivitamins, or Dairy Products</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_17_7"></a><a name="section-17.7"></a><p></p>
<h2>17.7 Darkening of the Tongue and/or Stool</h2>
<p class="First">Inform patients that PYLERA may cause temporary and harmless darkening of the tongue and/or black stool generally reversible within several days after treatment is stopped. Stool darkening should not be <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span> with <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span> (blood in the stool) [See <span class="Italics">Warnings and Precautions <a href="#section_5">(5.7)</a>]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_17_8"></a><a name="section-17.8"></a><p></p>
<h2>17.8 Dosing Information</h2>
<p class="First">Inform patients that each dose of PYLERA includes 3 capsules. Each dose of all 3 capsules should be taken 4 times a day, after meals and at bedtime for 10 days. One omeprazole 20 mg capsule should be taken twice a day with PYLERA after the morning and evening meal for 10 days.</p>
<p>Missed doses can be made up by continuing the normal dosing schedule until the medication is gone. They should not take double doses. If more than 4 doses are missed, contact their health-care provider [See <span class="Italics">Dosage and Administration <a href="#section_2">(2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_17_9"></a><a name="section-17.9"></a><p></p>
<h2>17.9 Administration with Fluids</h2>
<p class="First">Instruct patients to swallow the PYLERA capsules whole with a full glass of water (8 ounces).  Ingestion of adequate amounts of fluid, particularly with the bedtime dose, is recommended to reduce the risk of esophageal irritation and ulceration by tetracycline hydrochloride [See <span class="Italics">Dosage and Administration <a href="#section_2">(2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_17_10"></a><a name="section-17.10"></a><p></p>
<h2>17.10 Antibacterial Resistance</h2>
<p class="First">Patients should be counseled that antibacterial drugs including PYLERA should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>.  They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>).  When PYLERA is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed.  Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by PYLERA or other antibacterial drugs in the future.</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>Principal Display Panel</h1>Pylera<br>Â <br><div class="Figure"><img alt="image of package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7fe5d2db-c59d-4e15-acd7-f9df8eca45aa&amp;name=6151.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PYLERAÂ 		
					</strong><br><span class="contentTableReg">bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride (140 mg/125 mg/125 mg) capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6151(NDC:58914-600-21)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Bismuth subcitrate potassium</strong> (BISMUTH) </td>
<td class="formItem">Bismuth subcitrate potassium</td>
<td class="formItem">140Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Metronidazole</strong> (Metronidazole) </td>
<td class="formItem">Metronidazole</td>
<td class="formItem">125Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Tetracycline hydrochloride</strong> (Tetracycline) </td>
<td class="formItem">Tetracycline hydrochloride</td>
<td class="formItem">125Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (Opaque white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AxcanPharma;BMT</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6151-0</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">120  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050786</td>
<td class="formItem">08/18/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d6005cba-5d7d-4540-b1f2-5715e0870693</div>
<div>Set id: 7fe5d2db-c59d-4e15-acd7-f9df8eca45aa</div>
<div>Version: 1</div>
<div>Effective Time: 20110203</div>
</div>
</div>Â <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
